|Last Price$4.10||Day Change (%)-3.53%|
|Open Price$4.22||Day Change ($)-0.15|
|Day Range4.06–4.35||52-Week Range2.80–7.80|
As of Wed 8/31/2016 5:00:00 PM | USD
KERX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Keryx Biopharmaceuticals , Inc. and a Lead Plaintiff Deadline of October 3, 2016
Robbins Arroyo LLP: Keryx Biopharmaceuticals , Inc. ( KERX ) Misled Shareholders According to a Recently Filed Class Action
SHAREHOLDER ALERT: Rosen Law Firm Reminds Keryx Biopharmaceuticals Inc. Investors of Important Deadline in Class Action - KERX
INVESTOR ALERT: Class Action Lawsuit on Behalf of Investors in Keryx Biopharmaceuticals Announced by Holzer & Holzer
INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Keryx Biopharmaceuticals Inc.
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Keryx Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Keryx Pharmaceuticals, Inc. Investors and Encourages Investors to Contact the Firm
Glancy Prongay & Murray Commences Investigation on Behalf of Keryx Pharmaceuticals, Inc. Investors
Options on this firm's blockbuster cost a little but pay off big.